Skip to main content

Table 1 Test performance and Disease prevalence estimates

From: Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease

Test characteristics

Sensitivity

Specificity

Reference

Standard of care

0.35

0.65

Expert Opinion [16, 17]

FIB-4 (cut off 1.30)

0.84

0.74

[18, 19]

FIB-4 (cut off 3.25)

0.38

0.97

[18, 19]

ELF

0.80

0.90

[19, 20]

Fibroscan

0.82

0.84

[19, 21]

Population and disease characteristics

Transition probability

 

Prevalence of advanced fibrosis in the general population

0.075

[5]

  1. Published test characteristics of non-invasive liver fibrosis tests to detect advanced fibrosis (METAVIR ≥F3) in patients with non-alcoholic fatty liver disease